Zasocitinib Beats Deucravacitinib on Skin Clearance in Phase 3
Zasocitinib delivered superior skin clearance versus deucravacitinib in a Phase 3 head-to-head plaque psoriasis trial, raising the bar for oral TYK2-directed therapy.
Topic
Tyk2 Inhibitors
Topic
Tyk2 Inhibitors
Takeda reports zasocitinib superior to deucravacitinib
Takeda says its investigational TYK2 inhibitor zasocitinib beat deucravacitinib on efficacy in a head-to-head claim that could re…
Oral Therapies Position to Reshape Psoriasis and PsA Care
Linda Stein Gold, MD, tells AJMC that emerging oral therapies are set to transform treatment for both psoriasis and psoriatic art…